艾力斯(688578.SH)：甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示

智通财经2025-12-25

智通财经APP讯，艾力斯(688578.SH)发布公告，公司核心产品甲磺酸伏美替尼片(商品名“艾弗沙®”，简称“伏美替尼”)近日被国家药品监督管理局药品审评中心(简称“药审中心”)纳入拟突破性治疗品种公示名单，拟定适应症为具有表皮生长因子受体(EGFR)PACC突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗，公示期为2025年12月25日—2026年1月4日。甲磺酸伏美替尼片是...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594234512?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-25 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594234512","market":"us","top_or_hot":-1,"title":"艾力斯(688578.SH)：甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示","media":"智通财经","content":"<div>\n<p>智通财经APP讯，艾力斯(688578.SH)发布公告，公司核心产品甲磺酸伏美替尼片(商品名“艾弗沙®”，简称“伏美替尼”)近日被国家药品监督管理局药品审评中心(简称“药审中心”)纳入拟突破性治疗品种公示名单，拟定适应症为具有表皮生长因子受体(EGFR)PACC突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗，公示期为2025年12月25日—2026年1月4日。甲磺酸伏美替尼片是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385891.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾力斯(688578.SH)：甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾力斯(688578.SH)：甲磺酸伏美替尼片EGFRPACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 20:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1385891.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，艾力斯(688578.SH)发布公告，公司核心产品甲磺酸伏美替尼片(商品名“艾弗沙®”，简称“伏美替尼”)近日被国家药品监督管理局药品审评中心(简称“药审中心”)纳入拟突破性治疗品种公示名单，拟定适应症为具有表皮生长因子受体(EGFR)PACC突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗，公示期为2025年12月25日—2026年1月4日。甲磺酸伏美替尼片是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385891.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1385891.html","article_id":"2594234512","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594234512","pubTimestamp":1766665420,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，艾力斯 发布公告，公司核心产品甲磺酸伏美替尼片近日被国家药品监督管理局药品审评中心纳入拟突破性治疗品种公示名单，拟定适应症为具有表皮生长因子受体PACC突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗，公示期为2025年12月25日—2026年1月4日。目前，伏美替尼一线及二线治疗适应症均已纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688578":"艾力斯","BK0239":"医药制造"},"translate_title":"Ellis (688578. SH): Fumetinib mesylate tablets EGFRPACC mutation NSCLC first-line treatment indications included in the announcement of proposed breakthrough treatment varieties","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688578":1.5},"content_text":"智通财经APP讯，艾力斯(688578.SH)发布公告，公司核心产品甲磺酸伏美替尼片(商品名“艾弗沙®”，简称“伏美替尼”)近日被国家药品监督管理局药品审评中心(简称“药审中心”)纳入拟突破性治疗品种公示名单，拟定适应症为具有表皮生长因子受体(EGFR)PACC突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗，公示期为2025年12月25日—2026年1月4日。甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)，为公司自主研发的1类新药，属于小分子靶向药。临床研究结果显示，伏美替尼对多种EGFR突变展现出广泛的疗效，其一线治疗适应症、20外显子插入突变一线及二线治疗适应症先后纳入国家药品监督管理局(NMPA)药品评审中心(CDE)突破性治疗品种名单，20外显子插入突变一线治疗适应症同时还获得美国食品药品监督管理局(FDA)突破性疗法认定(BTD)。目前，伏美替尼一线及二线治疗适应症均已纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594234512","isCrawlerRequest":true}